References
Abrams JM. 2002. Competition and compensation: coupled to death in development and cancer. Cell 110(4):403–406.
Ambion Inc. 2006a. siRNA Target Finder. Available: http://www.ambion.com/techlib/misc/siRNA_finder.html [accessed 15 February 2007].
Ambion Inc. 2006b. siRNA Design Guidelines. Available: http://www.ambion.com/techlib/tb/tb_506.html [accessed 15 February 2007].
Bartke T, Siegmund D, Peters N, Reichwein M, Henkler F, Scheurich P, et al. 2001. p53 upregulates cFLIP, inhibits transcription of NFκB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells. Oncogene 20(5): 571–580.
Bettley FR, O'Shea JA. 1975. The absorption of arsenic and its relation to carcinoma. Br J Dermatol 92(5):563–568.
Budunova IV, Perez P, Vaden VR, Spiegelman VS, Slaga TJ, Jorcano JL. 1999. Increased expression of p50-NFκB and constitutive activation of NFκB transcription factors during mouse skin carcinogenesis. Oncogene 18(52):7423–7431.
Ding J, Li J, Xue C, Wu K, Ouyang W, Zhang D, et al. 2006. Cyclooxygenase-2 Induction by arsenite is through a nuclear factor of activated T-cell-dependent pathway and plays an antiapoptotic role in Beas-2B cells. J Biol Chem 281(34):24405–24413.
Feng L, Sun W, Xia Y, Tang WW, Chanmugam P, Soyoola E, et al. 1993. Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression. Arch Biochem Biophys 307(2):361–368.
Fischer SM, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubet RA, et al. 1999. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 25(4):231–240.
Han JA, Kim JI, Ongusaha PP, Hwang DH, Ballou LR, Mahale A, et al. 2002. P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis. Embo J 21(21):5635–5644.
Han SS, Kim K, Hahm ER, Park CH, Kimler BF, Lee SJ, et al. 2005. Arsenic trioxide represses constitutive activation of NFκB and COX-2 expression in human acute myeloid leukemia, HL-60. J Cell Biochem 94(4):695–707.
Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100(1):57–70.
Haque R, Mazumder DN, Samanta S, Ghosh N, Kalman D, Smith MM, et al. 2003. Arsenic in drinking water and skin lesions: dose-response data from West Bengal, India. Epidemiology 14(2):174–182.
Hecker E. 1987. Three stage carcinogenesis in mouse skin—recent results and present status of an advanced model system of chemical carcinogenesis. Toxicol Pathol 15(2):245–258.
Hickman JA. 2002. Apoptosis and tumourigenesis. Curr Opin Genet Dev 12(1):67–72.
Ho IC, Lee TC. 2002. Arsenite pretreatment attenuates benzo[a]pyrene cytotoxicity in a human lung adenocarcinoma cell line by decreasing cyclooxygenase-2 levels. J Toxicol Environ Health A 65(3–4):245–263.
Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. 2002. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277(5):3247–3257.
Hu Y, Baud V, Delhase M, Zhang P, Deerinck T, Ellisman M, et al. 1999. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKα subunit of IκB kinase. Science 284(5412):316–320.
Hu Y, Baud V, Oga T, Kim KI, Yoshida K, Karin M. 2001. IKKα controls formation of the epidermis independently of NFκB. Nature 410(6829):710–714.
Huang C, Ke Q, Costa M, Shi X. 2004. Molecular mechanisms of arsenic carcinogenesis. Mol Cell Biochem 255(1–2):57–66.
IARC (International Agency for Research on Cancer). 1980. Some Metals and Metallic Compounds. IARC Monogr Eval Carcinog Risk Chem Man 23:1–438.
Johnstone RW, Ruefli AA, Lowe SW. 2002. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108(2):153–164.
Klement JF, Rice NR, Car BD, Abbondanzo SJ, Powers GD, Bhatt PH, et al. 1996. IκBα deficiency results in a sustained NFκB response and severe widespread dermatitis in mice. Mol Cell Biol 16(5):2341–2349.
Krysan K, Reckamp KL, Dalwadi H, Sharma S, Rozengurt E, Dohadwala M, et al. 2005. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res 65(14):6275–6281.
Landolph JR. 1994. Molecular mechanisms of transformation of C3H/10T1/2 C1 8 mouse embryo cells and diploid human fibroblasts by carcinogenic metal compounds. Environ Health Perspect 102(suppl 3):119–125.
Li J, Chen H, Ke Q, Feng Z, Tang MS, Liu B, et al. 2004. Differential effects of polycyclic aromatic hydrocarbons on transactivation of AP-1 and NFκB in mouse epidermal cl41 cells. Mol Carcinog 40(2):104–115.
Li Q, Lu Q, Hwang JY, Buscher D, Lee KF, Izpisua-Belmonte JC, et al. 1999. IKK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev 13(10): 1322–1328.
Liu XH, Yao S, Kirschenbaum A, Levine AC. 1998. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 58(19):4245–4249.
Lowe SW, Lin AW. 2000. Apoptosis in cancer. Carcinogenesis 21(3):485–495.
National Center for Biotechnology Information. 2006a. BLAST (Basic Local Alignment Search Tool). Available: http://www.ncbi.nlm.nih.gov/BLAST/ [accessed 15 February 2007].
National Center for Biotechnology Information. 2006b. GenBank. Available: http://www.ncbi.nlm.nih.gov/Genbank/index.html [accessed 15 February 2007].
National Research Council. 1999. Arsenic in Drinking Water. Washington, DC:National Academy Press.
Nriagu JO. 2002. Environmental Chemistry of Arsenic. New York:Dekker.
Ouyang W, Li J, Ma Q, Huang C. 2006. Essential roles of PI-3K/Akt/IKKβ/NFκB pathway in cyclin D1 induction by arsenite in JB6 Cl41 cells. Carcinogenesis 27(4):864–873.
Pasparakis M, Courtois G, Hafner M, Schmidt-Supprian M, Nenci A, Toksoy A, et al. 2002. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 417(6891): 861–866.
Pi J, He Y, Bortner C, Huang J, Liu J, Zhou T, et al. 2005. Low level, long-term inorganic arsenite exposure causes generalized resistance to apoptosis in cultured human keratinocytes: potential role in skin co-carcinogenesis. Int J Cancer 116(1):20–26.
Rossman TG. 2003. Mechanism of arsenic carcinogenesis: an integrated approach. Mutat Res 533(1–2):37–65.
Ryan KM, Phillips AC, Vousden KH. 2001. Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 13(3):332–337.
Seitz CS, Lin Q, Deng H, Khavari PA. 1998. Alterations in NFκB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NFκB. Proc Natl Acad Sci USA 95(5):2307–2312.
Sheng H, Shao J, Washington MK, DuBois RN. 2001. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276(21): 18075–18081.
Smith WL, Garavito RM, DeWitt DL. 1996. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271(52):33157–33160.
Song L, Li J, Zhang D, Liu ZG, Ye J, Zhan Q, et al. 2006. IKKβ programs to turn on the GADD45α–MKK4–JNK apoptotic cascade specifically via p50 NFκB in arsenite response. J Cell Biol 175(4):607–617.
Subbaramaiah K, Bulic P, Lin Y, Dannenberg AJ, Pasco DS. 2001. Development and use of a gene promoter-based screen to identify novel inhibitors of cyclooxygenase-2 transcription. J Biomol Screen 6(2): 101–110.
Sun Y, Tang XM, Half E, Kuo MT, Sinicrope FA. 2002. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res 62(21):6323–6328.
Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, et al. 2002. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 62(12):3395–3401.
Trouba KJ, Germolec DR. 2004. Micromolar concentrations of sodium arsenite induce cyclooxygenase-2 expression and stimulate p42/44 mitogen-activated protein kinase phosphorylation in normal human epidermal keratinocytes. Toxicol Sci 79(2):248–257.
Tsai SH, Liang YC, Chen L, Ho FM, Hsieh MS, Lin JK. 2002. Arsenite stimulates cyclooxygenase-2 expression through activating IκB kinase and nuclear factor κB in primary and ECV304 endothelial cells. J Cell Biochem 84(4):750–758.
Tseng WP, Chu HM, How SW, Fong JM, Lin CS, Yeh S. 1968. Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J Natl Cancer Inst 40(3): 453–463.
Tsujii M, DuBois RN. 1995. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83(3):493–501.
Tsujii M, Kawano S, DuBois RN. 1997. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94(7): 3336–3340.
Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. 1998. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93(5):705–716.
Wang D, Buchanan FG, Wang H, Dey SK, DuBois RN. 2005. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res 65(5):1822–1829.
Wu Y, Mehew JW, Heckman CA, Arcinas M, Boxer LM. 2001. Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene 20(2):240–251.
Yan Z, Subbaramaiah K, Camilli T, Zhang F, Tanabe T, McCaffrey TA, et al. 2000. Benzo[a]pyrene induces the transcription of cyclooxygenase-2 in vascular smooth muscle cells. Evidence for the involvement of extracellular signal-regulated kinase and NFκB. J Biol Chem 275(7):4949–4955.
Yang C, Frenkel K. 2002. Arsenic-mediated cellular signal transduction, transcription factor activation, and aberrant gene expression: implications in carcinogenesis. J Environ Pathol Toxicol Oncol 21(4):331–342.
Yu HS, Liao WT, Chai CY. 2006. Arsenic carcinogenesis in the skin. J Biomed Sci 13(5):657–666.
Zornig M, Hueber A, Baum W, Evan G. 2001. Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta 1551(2):F1–37.
Zoumpourlis V, Solakidi S, Papathoma A, Papaevangeliou D. 2003. Alterations in signal transduction pathways implicated in tumour progression during multistage mouse skin carcinogenesis. Carcinogenesis 24(7): 1159–1165.
Last Updated: March 13, 2007